Psoriasis IL-17 Inhibitors: Report From the AAD Meeting
August 11, 2017|Cutis
Dr. Jeffrey Weinberg presented on IL-17 inhibitors at the summer meeting of the American Academy of Dermatology. He briefly reviews the data on secukinumab, brodalumab, and ixekizumab. He discusses the REMS (Risk Evaluation and Mitigation Strategies) program for brodalumab and use of ixekizumab for niche populations.